secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEVRO CORP (—)
CIK:        0001444380
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054492
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nevro Q1 revenue $101.9M (+5.8%), net loss $35.8M; raises adjusted EBITDA guidance, promotes Christoforou to COO
--------------------------------------------------------------------------------

- Q1 2024 worldwide revenue $101.9M, up 5.8% YoY; net loss from operations $35.8M; adjusted EBITDA loss $9.6M.
- FY2024 revenue guidance reaffirmed at $435–445M; adjusted EBITDA guidance raised to loss $5M to profit $2M.
- Additional restructuring steps announced to accelerate profitability and strengthen operations.
- Christofer Christoforou promoted to newly created COO role; he has been with Nevro for eight years.
- SI joint business: over 220 physicians trained on Nevro1™, one of three SI joint products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/nvro-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer